Johnson & Johnson reports strong quarter

Note: This section contains information in English only.
Source: Dukascopy Bank SA
In the second quarter of 2025, Johnson & Johnson reported strong results, with sales of $23.7 billion, up 5.8% from the same period last year. Operational sales, which exclude the impact of currency changes, grew by 4.6%, and adjusted operational sales rose 3.0%. The company earned $2.29 per share (GAAP), up 18.7%, while adjusted earnings per share were $2.77, slightly down from last year. Net earnings rose to $5.54 billion, while adjusted net earnings dipped slightly to $6.70 billion. Free cash flow for the year so far was about $6.2 billion, down from $7.5 billion last year.



Sales in the U.S. rose 7.8% to $13.5 billion, while international sales increased 3.2% to $10.2 billion. Johnson & Johnson also made progress in its pipeline, with key updates including FDA approval of IMAAVY for a rare muscle disease, priority review for a new bladder cancer drug (TAR-200), and promising data from the cancer treatment CARVYKTI. The company is also continuing development of its robotic surgery system, OTTAVA. Thanks to this strong performance, the company raised its full-year 2025 forecast. It now expects sales to grow 5.4% and raised its full-year earnings forecast to $10.85 per share (GAAP) and $10.68 adjusted. CEO Joaquin Duato said the results show the strength of J&J's mix of businesses and innovation pipeline, and he expects even stronger growth in the second half of the year.

Actual Topics

Subscribe to "Fundamental Analysis" feed

订阅
欲了解更多有关杜高斯贝银行差价合约/外汇交易平台,SWFX和其它相关交易详情,
请致电我们或要求回电。
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
欲了解更多有关杜高斯贝银行差价合约/外汇交易平台,SWFX和其它相关交易详情,
请致电我们或要求回电。
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.